Published in Retrovirology on April 16, 2013
High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. J Virol (2013) 1.15
Understanding HIV latency: the road to an HIV cure. Annu Rev Med (2015) 1.07
Which Antibody Functions are Important for an HIV Vaccine? Front Immunol (2014) 0.94
CD81 controls sustained T cell activation signaling and defines the maturation stages of cognate immunological synapses. Mol Cell Biol (2013) 0.86
Dendritic cell-lymphocyte cross talk downregulates host restriction factor SAMHD1 and stimulates HIV-1 replication in dendritic cells. J Virol (2014) 0.84
Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes. J Virol (2014) 0.81
Antiviral mechanism of polyanionic carbosilane dendrimers against HIV-1. Int J Nanomedicine (2016) 0.79
Retinoic acid imprints a mucosal-like phenotype on dendritic cells with an increased ability to fuel HIV-1 infection. J Immunol (2015) 0.79
Dendritic cells and the control of immunity. Nature (1998) 56.54
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell (2000) 14.43
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (1990) 9.72
HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J (1990) 9.34
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity (2007) 6.36
Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science (2003) 6.22
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med (1996) 5.35
V beta-specific stimulation of human T cells by staphylococcal toxins. Science (1989) 5.34
Direct observation of ligand recognition by T cells. Nature (2002) 5.21
Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol (1993) 5.17
HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med (2004) 5.08
Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol (2000) 4.87
T cell receptor signaling precedes immunological synapse formation. Science (2002) 4.56
Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med (2006) 4.23
T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node. Proc Natl Acad Sci U S A (2004) 3.99
Dendritic-cell interactions with HIV: infection and viral dissemination. Nat Rev Immunol (2006) 3.80
Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol (2007) 3.58
Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood (2003) 3.40
T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol (2003) 3.38
Histocompatibility antigen-activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors. J Exp Med (1977) 3.30
Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol (2006) 3.26
Superantigens interact with MHC class II molecules outside of the antigen groove. Cell (1990) 3.20
Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol (2010) 3.01
Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol (2001) 2.93
Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu Rev Immunol (1991) 2.93
HIV-1 membrane fusion: targets of opportunity. J Cell Biol (2000) 2.84
Functional antigen-independent synapses formed between T cells and dendritic cells. Nat Immunol (2001) 2.82
Directed egress of animal viruses promotes cell-to-cell spread. J Virol (2002) 2.72
HIV-1 trafficking to the dendritic cell-T-cell infectious synapse uses a pathway of tetraspanin sorting to the immunological synapse. Traffic (2005) 2.47
DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. J Exp Med (2004) 2.38
High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci U S A (2001) 2.32
Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. Virology (1999) 2.27
Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity (1997) 2.25
Retroviral spread by induction of virological synapses. Traffic (2004) 2.19
Requirement for an intact T-cell actin and tubulin cytoskeleton for efficient assembly and spread of human immunodeficiency virus type 1. J Virol (2007) 2.18
Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J Exp Med (2005) 2.04
Tuning immune responses: diversity and adaptation of the immunological synapse. Nat Rev Immunol (2005) 1.98
Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood (2008) 1.94
Human immunodeficiency virus type 1 virological synapse formation in T cells requires lipid raft integrity. J Virol (2005) 1.90
Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies. J Virol (2004) 1.89
Specificity of T-cell alloreactivity. Nat Rev Immunol (2007) 1.88
Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells. J Virol (2007) 1.87
Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J Virol (2002) 1.78
High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells. J Biol Chem (2004) 1.76
HIV traffics through a specialized, surface-accessible intracellular compartment during trans-infection of T cells by mature dendritic cells. PLoS Pathog (2008) 1.66
Functionally distinct transmission of human immunodeficiency virus type 1 mediated by immature and mature dendritic cells. J Virol (2007) 1.65
Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission. J Virol (2007) 1.64
Double-labelled HIV-1 particles for study of virus-cell interaction. Virology (2006) 1.49
Antigen-dependent and -independent Ca2+ responses triggered in T cells by dendritic cells compared with B cells. J Exp Med (1998) 1.46
Multiplicity of human immunodeficiency virus infections in lymphoid tissue. J Virol (2004) 1.43
Efficient virus transmission from dendritic cells to CD4+ T cells in response to antigen depends on close contact through adhesion molecules. Virology (1997) 1.39
Characterization of human immunodeficiency virus type 1 replication in immature and mature dendritic cells reveals dissociable cis- and trans-infection. J Virol (2007) 1.39
Differential susceptibility of naïve, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology (2006) 1.23
Resolution of de novo HIV production and trafficking in immature dendritic cells. Nat Methods (2007) 1.21
R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. J Leukoc Biol (2004) 1.18
HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4. Retrovirology (2008) 1.14
Role of ICAM-3 in the initial interaction of T lymphocytes and APCs. Nat Immunol (2002) 1.13
A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. J Med Virol (2007) 1.12
Biology of HIV mucosal transmission. Curr Opin HIV AIDS (2008) 1.06
Macropinocytosis and cytoskeleton contribute to dendritic cell-mediated HIV-1 transmission to CD4+ T cells. Virology (2008) 1.05
Intercellular adhesion molecule 1 (ICAM-1), but not ICAM-2 and -3, is important for dendritic cell-mediated human immunodeficiency virus type 1 transmission. J Virol (2009) 1.04
Dendritic cell-mediated HIV-1 transmission to T cells of LAD-1 patients is impaired due to the defect in LFA-1. Retrovirology (2006) 1.03
Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1. AIDS Res Hum Retroviruses (2000) 0.97
Current concepts of HIV transmission. Curr HIV/AIDS Rep (2007) 0.93
Characteristics of antigen-independent and antigen-dependent interaction of dendritic cells with CD4+ T cells. Eur J Immunol (1995) 0.91
The structural basis of T-cell allorecognition. Tissue Antigens (2004) 0.90
Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T lymphocytes. Blood (2012) 0.89
HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T cell activation. J Immunol (2012) 0.87
Dynamic imaging of cell-free and cell-associated viral capture in mature dendritic cells. Traffic (2011) 0.85
HIV-1 Nef enhances dendritic cell-mediated viral transmission to CD4+ T cells and promotes T-cell activation. PLoS One (2012) 0.85
Strong and durable TCR clustering at the T/dendritic cell immune synapse is not required for NFAT activation and IFN-gamma production in human CD4+ T cells. J Immunol (2004) 0.82
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med (2008) 7.31
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med (2004) 4.52
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med (2009) 3.52
Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 3.06
Update of the Drug Resistance Mutations in HIV-1. Top HIV Med (2008) 2.91
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med (2007) 2.79
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis (2006) 2.49
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS (2002) 2.29
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS (2002) 2.28
Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. Ann Intern Med (2003) 2.20
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis (2011) 2.10
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
Long-term effectiveness of infrared coagulation for the treatment of anal intraepithelial neoplasia grades 2 and 3 in HIV-infected men and women. AIDS (2013) 2.06
Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med (2005) 2.04
Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides. PLoS Biol (2012) 2.03
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]. Enferm Infecc Microbiol Clin (2011) 2.03
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]. Enferm Infecc Microbiol Clin (2012) 2.02
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS (2007) 1.98
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses (2008) 1.84
Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr (2012) 1.84
Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med (2005) 1.83
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother (2009) 1.79
Sialyllactose in viral membrane gangliosides is a novel molecular recognition pattern for mature dendritic cell capture of HIV-1. PLoS Biol (2012) 1.79
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis (2009) 1.79
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]. Med Clin (Barc) (2005) 1.78
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis (2013) 1.78
High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells. J Biol Chem (2004) 1.76
Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2005) 1.74
Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med (2011) 1.73
Drug resistance mutations in HIV-1. Top HIV Med (2003) 1.72
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J Exp Med (2006) 1.72
Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission. J Virol (2007) 1.64
A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med (2013) 1.62
Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med (2004) 1.62
Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest (2011) 1.61
Lipoid pneumonia: spectrum of clinical and radiologic manifestations. AJR Am J Roentgenol (2010) 1.59
Imaging findings in cardiac tamponade with emphasis on CT. Radiographics (2007) 1.58
Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. Blood (2008) 1.58
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr (2012) 1.53
Cell adhesion through alphaV-containing integrins is required for efficient HIV-1 infection in macrophages. Blood (2008) 1.53
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS (2005) 1.52
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS (2005) 1.52
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS (2007) 1.51
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One (2012) 1.48
Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP). AIDS (2011) 1.45
Copy number variation of KIR genes influences HIV-1 control. PLoS Biol (2011) 1.44
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med (2003) 1.44
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS (2003) 1.43
Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J (2002) 1.42
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]. Enferm Infecc Microbiol Clin (2004) 1.42
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther (2011) 1.41
Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. J Infect (2011) 1.39